Geode Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $45.3M | Buy |
|
|||||
|
2025
Q1 | $37.2M | Buy |
|
|||||
|
2024
Q4 | $36.3M | Sell |
|
|||||
|
2024
Q3 | $36.8M | Buy |
|
|||||
|
2024
Q2 | $29.1M | Buy |
|
|||||
|
2024
Q1 | $22.4M | Buy |
|
|||||
|
2023
Q4 | $25.5M | Buy |
|
|||||
|
2023
Q3 | $27.7M | Buy |
|
|||||
|
2023
Q2 | $27M | Buy |
|
|||||
|
2023
Q1 | $30.5M | Buy |
|
|||||
|
2022
Q4 | $39.8M | Buy |
|
|||||
|
2022
Q3 | $42.4M | Buy |
|
|||||
|
2022
Q2 | $34.7M | Buy |
|
|||||
|
2022
Q1 | $53.4M | Buy |
|
|||||
|
2021
Q4 | $44.6M | Buy |
|
|||||
|
2021
Q3 | $45.1M | Buy |
|
|||||
|
2021
Q2 | $49.2M | Buy |
|
|||||
|
2021
Q1 | $30.4M | Buy |
|
|||||
|
2020
Q4 | $19.8M | Buy |
|
|||||
|
2020
Q3 | $8.39M | Buy |
|
|||||
|
2020
Q2 | $10.5M | Buy |
|
|||||
|
2020
Q1 | $4.41M | Buy |
|
|||||
|
2019
Q4 | $6.59M | Buy |
|
|||||
|
2019
Q3 | $4.25M | Sell |
|
|||||
|
2019
Q2 | $5.63M | Buy |
|
|||||
|
2019
Q1 | $10.8M | Buy |
|
|||||
|
2018
Q4 | $9.91M | Buy |
|
|||||
|
2018
Q3 | $8.54M | Buy |
|
|||||
|
2018
Q2 | $5.75M | Buy |
|
|||||
|
2018
Q1 | $4.19M | Buy |
|
|||||
|
2017
Q4 | $4.02M | Buy |
|
|||||
|
2017
Q3 | $3.92M | Buy |
|
|||||
|
2017
Q2 | $3.64M | Sell |
|
|||||
|
2017
Q1 | $6.49M | Buy |
|
|||||
|
2016
Q4 | $3.27M | Buy |
|
|||||
|
2016
Q3 | $2.2M | Buy |
|
|||||
|
2016
Q2 | $1.4M | Sell |
|
|||||
|
2016
Q1 | $1.42K | Buy |
|
|||||
|
2015
Q4 | $4.92M | Buy |
|
|||||
|
2015
Q3 | $4.98M | Buy |
|
|||||
|
2015
Q2 | $6.06M | Buy |
|
|||||
|
2015
Q1 | $3.51M | Sell |
|
|||||
|
2014
Q4 | $5.11M | Buy |
|
|||||
|
2014
Q3 | $4.08M | Buy |
|
|||||
|
2014
Q2 | $4.71M | Buy |
|
|||||
|
2014
Q1 | $2.95M | Buy |
|
|||||
|
2013
Q4 | $1.68M | Buy |
|
|||||
|
2013
Q3 | $1.5M | Buy |
|
|||||
|
2013
Q2 | $268K | Buy |
|